Alpine Immune Sciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALPN and other ETFs, options, and stocks.About ALPN
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies.
CEOMitchell H. Gold
CEOMitchell H. Gold
Employees126
Employees126
HeadquartersSeattle, Washington
HeadquartersSeattle, Washington
Founded2007
Founded2007
Employees126
Employees126
ALPN Key Statistics
Market cap2.33B
Market cap2.33B
Price-Earnings ratio-29.51
Price-Earnings ratio-29.51
Dividend yield—
Dividend yield—
Average volume1.43M
Average volume1.43M
High today$39.29
High today$39.29
Low today$33.99
Low today$33.99
Open price$36.46
Open price$36.46
Volume977.30K
Volume977.30K
52 Week high$39.29
52 Week high$39.29
52 Week low$6.40
52 Week low$6.40
ALPN News
Yahoo Finance 3h
Alpine Immune Sciences, Inc. Q4 Earnings and Revenues Beat Estimates - Yahoo FinanceAlpine Immune Sciences, Inc. (ALPN) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.32 per share. This...
TipRanks 6h
Alpine Immune Sciences Highlights Key Communication Channels - TipRanks.com - TipRanksAn update from Alpine Immune Sciences Inc (ALPN) is now available. Alpine Immune Sciences actively communicates important updates to investors and the public v...
Yahoo Finance 7h
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results - Yahoo Finance-- Clinical data on povetacicept in IgA nephropathy will be updated at the upcoming WCN meeting, including follow up at 80 mg and initial data at 240 mg SC once...
Analyst ratings
100%
of 8 ratingsBuy
100%
Hold
0%
Sell
0%